The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.
 
Kara M. Schenk
No Relationships to Disclose
 
Julie E. Stein
No Relationships to Disclose
 
Sunandana Chandra
Honoraria - Array BioPharma; Bristol Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); exicure (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Diwakar Davar
Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences
Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Zeynep Eroglu
Consulting or Advisory Role - Elsevier; Genentech/Roche; Natera; Novartis; OncoSec; Regeneron; Sun Pharma
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Astellas Pharma; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; Eisai; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Mersana; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; Spring Bank; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Patrick Alexander Ott
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Oncorus; Pfizer (Inst); Xencor
Expert Testimony - Boehringer Ingelheim
 
Jeffrey A. Sosman
Honoraria - Apexian Pharmaceuticals; Array BioPharma; Bristol-Myers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Array BioPharma; Bristol-Myers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals
 
Vikram Aggarwal
Consulting or Advisory Role - Outset Medical
 
Megan Davis Schollenberger
No Relationships to Disclose
 
William Howard Sharfman
Honoraria - Array BioPharma; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; ION Pharma; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
 
Elad Sharon
No Relationships to Disclose
 
Serena M. Bagnasco
Research Funding - CareDX
 
Janis M. Taube
Stock and Other Ownership Interests - Akoya Biosciences
Consulting or Advisory Role - Akoya Biosciences; AstraZeneca/Merck; Bristol-Myers Squibb; Merck
Research Funding - Akoya Biosciences; Merck
Patents, Royalties, Other Intellectual Property - Multiplex IF image analysis
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - DNAtrix (I); Dracen (I); Dragonfly Therapeutics; Enara Bio (I); ManaT Bio (I); RAPT Therapeutics (I); Tizona Therapeutics, Inc. (I); TRex Bio (I); Trieza Therapeutics (I); WindMIL (I)
Consulting or Advisory Role - Amgen (I); AstraZeneca/MedImmune (I); Bristol-Myers Squibb/Celgene (I); Compugen (I); Dracen (I); Dragonfly Therapeutics; Five Prime Therapeutics; Immunocore; Immunomic Therapeutics (I); Janssen Oncology (I); RAPT Therapeutics (I); Shattuck Labs (I); Tempest Therapeutics (I); Tizona Therapeutics, Inc. (I); WindMIL (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Enara Bio (I)
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb (I); Immunonomic Therapeutics (I); WindMIL (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dragonfly Therapeutics
 
Daniel C. Brennan
Honoraria - CareDX; Veloxis
Consulting or Advisory Role - CareDX; Hansa Biopharma; Medeor Therapeutics; Sanofi
Research Funding - AlloVir; Amplyx Pharmaceuticals; CareDX; Natera
Patents, Royalties, Other Intellectual Property - Transplantation; UpToDate
Travel, Accommodations, Expenses - CareDX; Sanofi
 
Evan J. Lipson
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Genentech; Instil Bio; Macrogenics; Merck; Natera; Nektar; Novartis; Odonate Therapeutics; OncoSec; Pfizer; Rain Therapeutics; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sanofi/Regeneron (Inst)